| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| David B Wang, Robert D Dayton, Richard M Zweig, Ronald L Klei. Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response. Experimental neurology. vol 224. issue 1. 2010-06-28. PMID:20346943. |
histological staining for dopamine neurons and microglia matched the loss of dopaminergic markers and upregulation of immune response mrnas in the microarray data, respectively. |
2010-06-28 |
2023-08-12 |
rat |
| Valeria Rettori, Andrea De Laurentiis, Javier Fernandez-Solar. Alcohol and endocannabinoids: neuroendocrine interactions in the reproductive axis. Experimental neurology. vol 224. issue 1. 2010-06-28. PMID:20353777. |
cannabinoids also inhibit prolactin release from the lactotropes in the adenohypophysis acting locally and by increasing the release of hypothalamic dopamine mainly from tuberoinfundibular dopaminergic neurons in the external layer of the median eminence. |
2010-06-28 |
2023-08-12 |
Not clear |
| Massimo Contini, Bin Lin, Kazuto Kobayashi, Hideyuki Okano, Richard H Masland, Elio Raviol. Synaptic input of ON-bipolar cells onto the dopaminergic neurons of the mouse retina. The Journal of comparative neurology. vol 518. issue 11. 2010-06-28. PMID:20394057. |
in the retina, dopamine fulfills a crucial role in neural adaptation to photopic illumination, but the pathway that carries cone signals to the dopaminergic amacrine (da) cells was controversial. |
2010-06-28 |
2023-08-12 |
mouse |
| Florence Lev. Molecular genetics of ADHD: prospects for novel therapies. Expert review of neurotherapeutics. vol 2. issue 4. 2010-06-25. PMID:19810946. |
molecular genetic advances in relation to dopaminergic (dopamine transporter, dopamine d4 receptor and dopamine d5 receptor) genes, adrenergic, serotonergic and nicotinic receptor genes are reviewed. |
2010-06-25 |
2023-08-12 |
Not clear |
| Roberta Cavalcanti-Kwiatkoski, Rita Raisman-Vozari, Laure Ginestet, Elaine Del Be. Altered expression of neuronal nitric oxide synthase in weaver mutant mice. Brain research. vol 1326. 2010-06-25. PMID:20219442. |
the aim of the present study was to analyze the nitric oxide and dopaminergic systems in selected brain regions of homozygous weaver mice at different postnatal ages corresponding to specific stages of the dopamine loss. |
2010-06-25 |
2023-08-12 |
mouse |
| Päivi Lindholm, Mart Saarm. Novel CDNF/MANF family of neurotrophic factors. Developmental neurobiology. vol 70. issue 5. 2010-06-23. PMID:20186704. |
in line, drosophila manf is needed for the maintenance of dopaminergic neurites and dopamine levels in the fly, suggesting that the function of cdnf/manf proteins is evolutionary conserved. |
2010-06-23 |
2023-08-12 |
rat |
| W M Hol, R van der Zwaard, A Hovestadt, H J G M van Mege. [Dopamine dysregulation syndrome in a patient with Parkinson's disease; a case report]. Tijdschrift voor psychiatrie. vol 52. issue 4. 2010-06-22. PMID:20503167. |
we illustrate this link by focusing on a patient suffering from parkinson's who received not only deep brain stimulation but also excessive amounts of dopaminergic drugs, a combination that resulted in hypomania which is also known as dopamine dysregulation syndrome. |
2010-06-22 |
2023-08-12 |
Not clear |
| Jason M Williams, Dejan Milatovic, John C Gore, Michael Aschner, Malcolm J Aviso. Chronic exposure to manganese alters brain responses to amphetamine: a pharmacological magnetic resonance imaging study. Toxicological sciences : an official journal of the Society of Toxicology. vol 114. issue 2. 2010-06-21. PMID:20061340. |
the parkinsonian symptoms and increased mn accumulation in dopaminergic (daergic) neurons of the basal ganglia implicate impaired dopamine signaling in the neurotoxic effects of chronic manganese overexposure. |
2010-06-21 |
2023-08-12 |
rat |
| F Pérez-Sánchez, M Milán, P Buendía, M Cano-Jaimez, S Ambrosio, A Rosenthal, I Fariña. Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice. Neuroscience. vol 167. issue 2. 2010-06-17. PMID:20156526. |
surprisingly, cultured transgenic ventral mesencephalic fetal dopaminergic neurons exhibit complete resistance to cell death induced by 1-methyl-4-phenylpyridinium ion (mpp(+)) intoxication, without changes in dopamine transporter (dat) surface levels. |
2010-06-17 |
2023-08-12 |
mouse |
| Takahiro Iizuka, Fumihiko Sakai, Hideki Mochizuk. [Update on anti-NMDA receptor encephalitis]. Brain and nerve = Shinkei kenkyu no shinpo. vol 62. issue 4. 2010-06-17. PMID:20420172. |
considering the symptomatology of anti-nmdar encephalitis and the results of cell culture analysis, we speculate that the overall antibody-mediated inhibition of nmdars expressed on gabaergic interneurons, glutamatergic neurons and dopaminergic neurons may cause neuropsychiatric symptoms and dyskinesias via dopamine and glutamate dysregulation. |
2010-06-17 |
2023-08-12 |
Not clear |
| Mark D Humphries, Tony J Prescot. The ventral basal ganglia, a selection mechanism at the crossroads of space, strategy, and reward. Progress in neurobiology. vol 90. issue 4. 2010-06-14. PMID:19941931. |
dopamine's key role in learning is reviewed within the three current major computational frameworks; we also show that the shell-based basal ganglia sub-circuits are well placed to generate the phasic burst and dip responses of dopaminergic neurons. |
2010-06-14 |
2023-08-12 |
Not clear |
| Saviana Di Giovanni, Simona Eleuteri, Katerina E Paleologou, Guowei Yin, Markus Zweckstetter, Pierre-Alain Carrupt, Hilal A Lashue. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. The Journal of biological chemistry. vol 285. issue 20. 2010-06-14. PMID:20150427. |
current therapeutic strategies for treating pd offer mainly transient symptomatic relief and aim at the restitution of dopamine levels to counterbalance the loss of dopaminergic neurons. |
2010-06-14 |
2023-08-12 |
Not clear |
| L Hunter Randy, Bing Guoyin. Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease. Current neuropharmacology. vol 5. issue 1. 2010-06-11. PMID:18615152. |
this implies there is more to the treatment of pd than just restoring dopamine or the dopaminergic neurons, and that a broader spectrum of factors must be changed in order to restore environmental homeostasis. |
2010-06-11 |
2023-08-12 |
Not clear |
| L Hunter Randy, Bing Guoyin. Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease. Current neuropharmacology. vol 5. issue 1. 2010-06-11. PMID:18615152. |
pharmacological agents that can protect against progressive neuronal degeneration, increase the level of dopamine in the nigrostriatal system, or restore the dopaminergic system offer various avenues for the treatment of pd. |
2010-06-11 |
2023-08-12 |
Not clear |
| T J Vol. Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate. Current neuropharmacology. vol 6. issue 4. 2010-06-11. PMID:19587858. |
in addition, methylphenidate has the intriguing ability to provide neuroprotection from the neurotoxic effects of methamphetamine and perhaps also parkinson's disease; both of which may likely involve the abnormal accumulation of cytoplasmic dopamine inside dopaminergic neurons and the resulting formation of dopamine-associated reactive oxygen species. |
2010-06-11 |
2023-08-12 |
Not clear |
| T J Vol. Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate. Current neuropharmacology. vol 6. issue 4. 2010-06-11. PMID:19587858. |
these may include 1) direct interactions between methylphenidate and the neuronal dopamine transporter which may attenuate or prevent the entry of methamphetamine into dopaminergic neurons and may also decrease the synthesis of cytoplasmic dopamine through a d2 receptor-mediated signal cascade process, and 2) indirect effects upon the functioning of the vesicular monoamine transporter-2 which may increase vesicular dopamine sequestration through both vesicle trafficking and the kinetic upregulation of the vesicular monoamine transporter-2 protein. |
2010-06-11 |
2023-08-12 |
Not clear |
| T J Vol. Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate. Current neuropharmacology. vol 6. issue 4. 2010-06-11. PMID:19587858. |
understanding these neuropharmacological mechanisms of methylphenidate neuroprotection may provide important insights into the physiologic regulation of dopaminergic systems as well as the pathophysiology of a variety of disorders involving abnormal dopamine disposition ranging from substance abuse to neurodegenerative diseases such as parkinson's disease. |
2010-06-11 |
2023-08-12 |
Not clear |
| Paola Devoto, Giovanna Flor. On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons? Current neuropharmacology. vol 4. issue 2. 2010-06-09. PMID:18615131. |
on the other hand, drugs selectively acting on dopaminergic transmission produced modest changes in extracellular da in mpfc, and had no effect on the occipital or parietal cortex.acute administration of morphine did not increase da levels in the pfc (where na is diminished), in contrast with augmented dopaminergic neuronal activity; moreover, during morphine withdrawal both da and na levels increased, in spite of a diminished dopaminergic activity, both increases being antagonised by clonidine but not quinpirole administration.extensive 6-hydroxy dopamine lesion of the ventral tegmental area (vta) decreases below 95% of control both intra- and extracellular da and dopac in the nucleus accumbens, but only partially or not significantly in the mpfc and parietal cortex.the above evidence points to a common origin for na and da in the cerebral cortex and suggests the possible utility of noradrenergic system modulation as a target for drugs with potential clinical efficacy on cognitive functions. |
2010-06-09 |
2023-08-12 |
rat |
| Marjan Jahanshahi, Leonora Wilkinson, Harpreet Gahir, Angeline Dharmaindra, Angeline Dharmarinda, Angeline Dharminda, David A Lagnad. Medication impairs probabilistic classification learning in Parkinson's disease. Neuropsychologia. vol 48. issue 4. 2010-06-09. PMID:20006629. |
the significant deterioration of learning on the wpt in pd patients when on compared to off medication supports the proposal that tonic increase of dopamine with dopaminergic medication masks phasic changes in dopamine release essential for learning. |
2010-06-09 |
2023-08-12 |
Not clear |
| Carolina Chavez, Marianne Hollaus, Elizabeth Scarr, Geoff Pavey, Andrea Gogos, Maarten van den Buus. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain research. vol 1321. 2010-06-09. PMID:20079719. |
the aim of the present study was to elucidate the effect of estrogen on dopaminergic and serotonergic regulation of prepulse inhibition (ppi) by measuring its effects on the density of dopamine transporters (dat), dopamine d(1) and d(2) receptors, serotonin transporters (sert), serotonin-1a (5-ht(1a)) and 5-ht(2a) receptors using radioligand binding autoradiography. |
2010-06-09 |
2023-08-12 |
rat |